Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2024-04-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于拟购买董监高责任险的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's plan to purchase directors and officers liability insurance (董监高责任险). It details the insurance plan, the approval process by the board and supervisory committee, and the submission of the proposal to the upcoming shareholders' meeting for approval. The document does not contain financial statements, audit results, or detailed financial performance data. It is a regulatory announcement about a corporate governance and risk management matter, specifically related to insurance for directors and officers. The document length is short (1212 characters) and it is an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-18 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the second meeting of the sixth supervisory board of the company, including approvals of various reports such as the 2023 annual report, financial statements, internal control report, and the 2024 first quarter report. It also includes approvals related to remuneration, stock incentive plans, capital reduction, auditor appointment, and election of a new supervisor. The document repeatedly states that the detailed reports are available on an external website (cninfo.com.cn) and that these resolutions will be submitted to the 2023 annual general meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal announcement of the supervisory board's meeting decisions and approvals. Given the nature of the content—meeting resolutions and approvals by the supervisory board—and the absence of the full reports or detailed financial data, this document fits best into the category of Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is under 5,000 characters, and it references reports being available elsewhere, reinforcing that this is an announcement rather than the reports themselves.
2024-04-18 Chinese
公司章程（2024年4月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 迪瑞医疗科技股份有限公司 (Dirui Industrial Co., Ltd). It contains detailed company governance rules, including chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, party committee and party building, financial accounting system, profit distribution and audit, notices and announcements, mergers, capital changes, delisting, and amendments to the articles. The content is a comprehensive governance document outlining the company's internal rules, board structure, shareholder rights, and corporate governance practices. There is no indication that this is an announcement or a report publication notice; it is the actual governance charter of the company. Therefore, the document fits the category of Governance Information (CGR).
2024-04-18 Chinese
独立董事述职报告（安明友）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report" for the company. It details the independent director's attendance at board meetings, opinions on various company matters, communication with audit institutions, and other governance-related activities during the year 2023. The content focuses on the independent director's duties, governance, and oversight rather than financial results or audit opinions alone. It is not a full annual report (10-K), audit report (AR), or earnings release (ER). It is a governance-related report describing the independent director's role and activities, which fits best under Board/Management Information (MANG) as it relates to board members' duties and governance activities. The document length is under 5,000 characters but contains substantive content about the independent director's work, not just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2024-04-18 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2023 年度财务决算报告' which translates to '2023 Annual Financial Settlement Report'. It contains detailed financial statements including balance sheets, income statements, cash flow statements, and notes for the fiscal year ending December 31, 2023. The document includes audited financial data with a standard unqualified audit opinion from a CPA firm. It provides comprehensive financial metrics, analysis of financial position, operating results, and cash flows for the full year 2023 compared to 2022. The length of the document (6092 characters) and the detailed financial content indicate it is a full annual financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K) as it covers the company's full financial performance for the year. FY 2023
2024-04-18 Chinese
关于迪瑞医疗科技股份有限公司2022年限制性股票激励计划调整回购价格及回购注销限制性股票事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of repurchase price and repurchase cancellation of restricted stocks under the 2022 restricted stock incentive plan of a company. It details the legal compliance, approvals, and authorizations related to the stock incentive plan and repurchase actions. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital/financing activity (stock repurchase and cancellation). It is not a simple announcement but a detailed legal opinion on a financing-related corporate action. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5924 characters) and content confirm it is a substantive legal opinion, not a brief announcement or certification, so it is not RNS or RPA.
2024-04-18 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.